| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total other income | 62 | 800 | ||
| Net loss | -26,451 | -40,950 | ||
| Unrealized gain on marketable securities | 86 | 8 | ||
| Comprehensive loss | -26,365 | -40,942 | ||
| Net loss per common share, basic (in dollars per share) | -0.44 | -0.68 | ||
| Net loss per common share, diluted (in dollars per share) | -0.44 | -0.68 | ||
| Weighted-average shares outstanding diluted (in shares) | 60,573,425 | 60,573,425 | ||
| Weighted-average shares outstanding, basic (in shares) | 60,573,425 | 60,573,425 | ||
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)